Newronika Secures €13.6 Million in Series B Funding to Advance DBS Technology
On February 13, 2025, Newronika, a front-runner in advanced deep brain stimulation (DBS) technologies, announced the successful completion of its Series B funding round, securing an impressive €13.6 million. This round was primarily led by a new investor, the Fondazione ENEA Tech e Biomedical, along with the participation of existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. This significant influx of capital will be instrumental in helping Newronika expand the clinical validation and market reach of its proprietary adaptive DBS system. Developed to provide precision therapy, this innovative platform aims to enhance symptom relief while simultaneously minimizing the side effects experienced by patients suffering from Parkinson's disease.
The funds raised will also further the development of the company's product pipeline, enable the recruitment of top talent, and facilitate strategic partnerships that will bolster Newronika's position at the intersection of medical technology and neuroscience.
Newronika’s ongoing momentum is evidenced by its recent achievements, which include support from the Michael J. Fox Foundation, an Investigational Device Exemption (IDE) approval, and now this substantial funding round. Each of these milestones underscores the company’s commitment to pioneering a paradigm shift in neuromodulation. The adaptive DBS technology is seen as the future direction of personalized brain stimulation, and Newronika aspires to lead this evolution.
“We are thrilled with the strong backing from both new and existing investors,” stated Dr. Lorenzo Rossi, co-founder and CEO of Newronika. “This Series B funding round validates our mission to transform how deep brain stimulation is applied. Our goal is to integrate real-time neural data and machine learning seamlessly into our DBS systems, enabling the creation of truly personalized therapies that surpass the capabilities of currently available devices.”
Maria Cristina Porta, General Manager of ENEA Tech e Biomedical, highlighted the remarkable potential of Newronika to revolutionize the treatment of movement disorders globally. “Newronika and its adaptive DBS platform represent extraordinary promise for the care of patients with movement disorders worldwide. Their innovative approach, which allows for personalized neuromodulation in real time, aligns perfectly with our vision of supporting groundbreaking medical technologies,” she noted. “Investing in such technologies is not only about caring for health – it also means creating value and driving innovation within our country’s ecosystem.”
Similarly, Davide Turco, CEO of Indaco, expressed pride in supporting Newronika through its upcoming clinical and commercial phases. Comments by Turco reflect a firm conviction that Newronika's adaptive DBS system has the potential to significantly enhance the quality of life for many Parkinson's patients.
Along with the excitement surrounding the funding, Claudio Giuliano, Chairman of Newronika, remarked, “This successful Series B funding round cements our strategic vision and commitment to pushing the boundaries of DBS technology for the benefit of patients.”
About the Investors
ENEA Tech e Biomedical focuses on projects with high impact in biotechnology, medical devices, and biosciences, supporting transformative solutions for global health challenges. Indaco Venture Partners SGR is one of Italy's largest venture capital firms, investing in innovative healthcare and technology solutions. Innogest SGR specializes in medical technology and digital health, utilizing its expertise to nurture innovative healthcare startups. Wille Finance is a Swiss multi-family office committed to impactful investments in healthcare and technology sectors. TNBT Capital, based in Paris, invests in groundbreaking technologies in neuromodulation and neurotechnology. F3F is an Italian venture capital company dedicated to innovative medical technology firms that redefine patient care.
About Newronika
Newronika is reshaping deep brain stimulation (DBS) with its adaptive platform employing real-time patient data to optimize therapy. Headquartered in Milan, Italy, the company aims to push the boundaries of neuromodulation beyond conventional limits. With ongoing research collaborations, CE marking for its technology, and now an FDA IDE, Newronika stands at the forefront of next-generation therapeutic innovation in neurological disorders. For more information, visit Newronika's website or follow them on LinkedIn.
The funds raised will also further the development of the company's product pipeline, enable the recruitment of top talent, and facilitate strategic partnerships that will bolster Newronika's position at the intersection of medical technology and neuroscience.
Newronika’s ongoing momentum is evidenced by its recent achievements, which include support from the Michael J. Fox Foundation, an Investigational Device Exemption (IDE) approval, and now this substantial funding round. Each of these milestones underscores the company’s commitment to pioneering a paradigm shift in neuromodulation. The adaptive DBS technology is seen as the future direction of personalized brain stimulation, and Newronika aspires to lead this evolution.
“We are thrilled with the strong backing from both new and existing investors,” stated Dr. Lorenzo Rossi, co-founder and CEO of Newronika. “This Series B funding round validates our mission to transform how deep brain stimulation is applied. Our goal is to integrate real-time neural data and machine learning seamlessly into our DBS systems, enabling the creation of truly personalized therapies that surpass the capabilities of currently available devices.”
Maria Cristina Porta, General Manager of ENEA Tech e Biomedical, highlighted the remarkable potential of Newronika to revolutionize the treatment of movement disorders globally. “Newronika and its adaptive DBS platform represent extraordinary promise for the care of patients with movement disorders worldwide. Their innovative approach, which allows for personalized neuromodulation in real time, aligns perfectly with our vision of supporting groundbreaking medical technologies,” she noted. “Investing in such technologies is not only about caring for health – it also means creating value and driving innovation within our country’s ecosystem.”
Similarly, Davide Turco, CEO of Indaco, expressed pride in supporting Newronika through its upcoming clinical and commercial phases. Comments by Turco reflect a firm conviction that Newronika's adaptive DBS system has the potential to significantly enhance the quality of life for many Parkinson's patients.
Along with the excitement surrounding the funding, Claudio Giuliano, Chairman of Newronika, remarked, “This successful Series B funding round cements our strategic vision and commitment to pushing the boundaries of DBS technology for the benefit of patients.”
About the Investors
ENEA Tech e Biomedical focuses on projects with high impact in biotechnology, medical devices, and biosciences, supporting transformative solutions for global health challenges. Indaco Venture Partners SGR is one of Italy's largest venture capital firms, investing in innovative healthcare and technology solutions. Innogest SGR specializes in medical technology and digital health, utilizing its expertise to nurture innovative healthcare startups. Wille Finance is a Swiss multi-family office committed to impactful investments in healthcare and technology sectors. TNBT Capital, based in Paris, invests in groundbreaking technologies in neuromodulation and neurotechnology. F3F is an Italian venture capital company dedicated to innovative medical technology firms that redefine patient care.
About Newronika
Newronika is reshaping deep brain stimulation (DBS) with its adaptive platform employing real-time patient data to optimize therapy. Headquartered in Milan, Italy, the company aims to push the boundaries of neuromodulation beyond conventional limits. With ongoing research collaborations, CE marking for its technology, and now an FDA IDE, Newronika stands at the forefront of next-generation therapeutic innovation in neurological disorders. For more information, visit Newronika's website or follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.